Nutrileads’ BeniCaros prebiotic gains immune health claims in Australia and New Zealand
The claims regard supporting an antiviral response to the common cold as well as reducing the severity and duration of common cold symptoms, among other benefits.
BeniCaros, a prebiotic ingredient from NutriLeads BV (Wageningen, the Netherlands), is now authorized to use eight new immune-health claims in Australia and New Zealand. The regulatory agency Food Standards Australia and New Zealand (FSANZ) recently approved the claims following a systematic review of the scientific evidence NutriLeads submitted. BeniCaros is made from upcycled carrot pomace.
The claims include:
- Supports/aids/assists/promotes/boosts/stimulates/improves immune health
- Reduces the severity and duration of symptoms of common cold (rhinovirus) infection
- Stimulates innate immune and antiviral response to common cold (rhinovirus) infection
- Faster and more effective immune response
- Supports immune defenses
- Supports healthy immune system function and response
- Accelerates local protective antiviral immune response
- Immunomodulatory effect on immune cells
“In addition to the FSANZ claims, BeniCaros is permitted for use in dietary supplements regulated by Australian Therapeutic Goods Administration (TGA), without restriction,” the company’s press release adds.
BeniCaros, whose prebiotic fiber is known scientifically as RG-I (rhamnogalacturonan-I), can be taken at a 300-mg daily serving. It is said to train the immune system to respond smarter, faster, and stronger.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
